9 results about "Anticoagulation Activity" patented technology

The invention provides a sustained-release microneedle for treating ill-conditioned pregnancy and a preparation method and application thereof, and relates to the technical field of biological medicines.The sustained-release microneedle for treating ill-conditioned pregnancy comprises a base and a needle tip on the base, the needle tip part of the gel microneedle is made of heparin medicine, and the needle tip part of the gel microneedle is made of gelatin. The heparin medicine comprises heparin, heparin sodium, low-molecular heparin, low-molecular heparin sodium or low-molecular heparin calcium; the needle point part comprises a heparin photo-crosslinking monomer, and the base comprises a biocompatible polymer matrix. The sustained-release microneedle for treating pathological pregnancy provided by the embodiment of the invention has good mechanical strength, skin permeability and anticoagulant activity, can reduce skin bruises caused by subcutaneous injection of heparin, improves abortion caused by infection and inflammation and abortion caused by APS (anti-phospholipid antibody syndrome), can realize sustained release of drugs and increase of drug loading capacity, and has good application prospects. Sustainable drug delivery is achieved, and frequent injection is avoided.

The invention relates to the technical field of medical materials, and particularly discloses a heparinized polycaprolactone coating as well as a preparation method and application thereof. The preparation method of the heparinized polycaprolactone coating comprises the following steps: adding poloxamer 188 into an MES buffer solution, adding heparin, uniformly stirring, then adding EDC and NHS, and stirring for 40-120 minutes to prepare an activated heparin solution; and dropwise adding the polycaprolactone solution into the activated heparin solution, reacting at room temperature for 90-180 minutes, then dissolving the conjugate into chloroform through rotary evaporation, washing with water, drying with anhydrous MgSO4, precipitating with methanol, filtering the precipitate, and drying in vacuum at 30-40 DEG C to obtain the polycaprolactone heparin. According to the prepared heparinized polycaprolactone coating, local release of heparin is remarkably reduced, and the continuous anticoagulation effect is achieved; and the anticoagulant activity of heparin is reserved, and the coating with good stability is obtained.

The application discloses a method for screening a quality marker of Radix Paeoniae Rubra based on an anticoagulation spectrum-effect relationship, mainly comprising the following steps: preparing control samples and Radix Paeoniae Rubra sample materials, determining a preparation method of the Radix Paeoniae Rubra sample and optimal chromatographic conditions for separating the Radix Paeoniae Rubra sample, and constructing a fingerprint of the Radix Paeoniae Rubra sample; using a blood coagulation instrument to determine an in-vitro anticoagulation activity of Radix Paeoniae Rubra extracts; analyzing experimental data to determine the quality marker of Radix Paeoniae Rubra based on the anticoagulation spectrum-effect relationship. The efficacy and common peaks of the fingerprint are analyzed by a grey correlation degree analysis method, and the quality marker of Radix Paeoniae Rubra for anticoagulation is screened. The method overcomes the fact that the prior art does not have a related technology for determining the quality marker of Radix Paeoniae Rubra for anticoagulation by the grey correlation degree analysis method.

The application provides an intelligent atrial fibrillation anticoagulation bleeding risk assessment system and method. The system comprises a patient data acquisition module for acquiring gene mutation site data, drug exposure data, anticoagulation activity data, clinical feature data and follow-up bleeding event data; a data checking and fusing module for quality checking, time alignment and feature fusing of the data to generate anticoagulation bleeding correlation features; a site correlation modeling module for constructing a conduction correlation model between the gene mutation site and the drug exposure offset, the anticoagulation activity offset and the follow-up bleeding event based on the anticoagulation bleeding correlation features; and a risk assessment module for determining the anticoagulation bleeding risk representation of a target atrial fibrillation patient according to the conduction correlation model, decomposing the anticoagulation bleeding risk representation into risk sources, and generating an intelligent atrial fibrillation anticoagulation bleeding risk assessment result containing risk level and risk source information. The application can improve the assessment accuracy, enhance individual identification and improve the result interpretability.

The present application provides a heparin sodium composition with redness-removing repair and anti-wrinkle firming effect, and a preparation process and application thereof. The composition takes carboxymethylated low molecular heparin sodium liposome as a core active ingredient, and is compounded with a redness-removing repair compound and an elastin compound, and is supplemented with a penetration enhancer, an ionic liquid enhancer, a film-forming polymer and an anti-degradation stabilizer. Through the ionic liquid composite liposome technology combined with a triple penetration system, the transdermal efficiency and bioavailability of heparin sodium are significantly improved. The carboxymethylation modification reduces the anticoagulant activity and eliminates the risk of bleeding. The anti-degradation stabilizer ensures the stability of the product. The composition can effectively improve the problems of facial and periorbital redness, red blood vessels, dry lines and relaxation, and has high safety, and can be widely applied to the preparation of eye creams, face creams and other cosmetics.

The application belongs to the field of medicine, and discloses a compound or a pharmaceutically acceptable salt, a stereoisomer, a solvate thereof, the structure of which is shown in formula I. In vitro binding efficacy experiments and toxicity experiments of low molecular heparin and the triazine compound of the application show that the triazine compound can produce good combination with low molecular heparin, and can reverse the anticoagulation of heparin, is a safe and low-toxic small molecule compound, and can be used for preparing a medicine for reversing the anticoagulation activity of heparin, treating and / or preventing adverse reactions and diseases caused by excessive heparin anticoagulation. The application discloses the use of the triazine compound or the pharmaceutically acceptable salt, the stereoisomer, the solvate thereof in preparing an anticoagulant reversing agent. The application discloses the use of the triazine compound or the pharmaceutically acceptable salt, the stereoisomer, the solvate thereof in preparing a medicine for treating side effects of excessive anticoagulation caused by using heparin to treat diseases, and preparing a medicine for treating surgical operations in which the anticoagulation activity of heparin needs to be reversed.

Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.

This invention relates to the field of biomedical polymer materials technology, specifically to a polyethersulfone-based material with blood purification and anticoagulation functions, its preparation method, and its applications. The polyethersulfone-based material uses polyethersulfone as the main component, and a stable multi-coordination network structure is constructed by introducing terpyridine ligands and multivalent metal ions at the molecular level. Furthermore, the anticoagulant active molecules argatroban or heparin are immobilized on its surface, achieving selective adsorption of blood toxins and synergistic regulation of the anticoagulation reaction. The material is prepared using a process combining phase inversion membrane formation technology and surface coordination modification, resulting in a composite interface on the membrane surface rich in hydrophilic groups and a stable anticoagulant layer, significantly improving blood compatibility and membrane flux stability. This composite membrane can simultaneously perform purification and anticoagulation functions in hemodialysis, hemofiltration, and extracorporeal circulation systems, exhibiting good mechanical strength, chemical stability, and biosafety. The preparation route of this invention is simple, the parameters are controllable, and it is suitable for large-scale production.